Skip to main content
. 2018 Jun 28;9:1510. doi: 10.3389/fimmu.2018.01510

Figure 2.

Figure 2

Baricitinib suppresses CD80/CD86 expression on dendritic cells (DCs). Immature monocyte-derived dendritic cells were cultured with or without baricitinib and tofacitinib during lipopolysaccharide stimulation for 48 h. The DC phenotype was evaluated using flow cytometry. (A) Expression of HLA-DR, CD80, and CD86. (B) Representative histogram data of HLA-DR, CD80, and CD86 expression. (C) Rate of viable cells (annexin Vneg/propidium iodideneg). (D) Expression of CD80 and CD86 in the presence of baricitinib and tofacitinib. Data are mean ± SD of three different donors per group. *p < 0.05 and **p < 0.01 (by Student’s t-test).